

B21

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 January 2003 (30.01.2003)


PCT

(10) International Publication Number
WO 03/008603 A2

- (51) International Patent Classification⁷: C12P 13/00 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/EP02/07351
- (22) International Filing Date: 3 July 2002 (03.07.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
101 35 051.1 18 July 2001 (18.07.2001) DE
60/306,867 23 July 2001 (23.07.2001) US
- (71) Applicant (for all designated States except US): DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HERMANN, Thomas [DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).
- (74) Common Representative: DEGUSSA AG; Intellectual Property Management, Patents and Trademarks, Location Hanau, P.O.Box 13 45, 63403 Hanau (DE).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only
- Published:
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED ASPA GENE



BEST AVAILABLE COPIE

BEST AVAILABLE COPY

WO 03/008603 A2

7. The International Bureau may, at any time, determine that the classification of an international application is not appropriate for the protection of the subject matter of the application, and may, in accordance with the provisions of the Patent Cooperation Treaty, change the classification of the application. The International Bureau may also, at any time, determine that the classification of an international application is not appropriate for the protection of the subject matter of the application, and may, in accordance with the provisions of the Patent Cooperation Treaty, change the classification of the application.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**Process for the Preparation of L-Amino Acids using Strains
of the Enterobacteriaceae Family which Contain an
Attenuated aspA Gene**

Field of the Invention

5 This invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine, using strains of the Enterobacteriaceae family in which the aspA gene is attenuated.

Prior Art

10 L-Amino acids, in particular L-threonine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

15 It is known to prepare L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g. 20 stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

25 Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue α -amino- β -hydroxyvaleric acid (AHV), or are auxotrophic for 30 metabolites of regulatory importance and produce L-amino acid, such as e.g. L-threonine, are obtained in this invention.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of strains of the Enterobacteriaceae family which produce L-amino acids, by amplifying individual amino acid

- 5 biosynthesis genes and investigating the effect on the
production.

Object of the Invention

The object of the invention is to provide new measures for improved fermentative preparation of L-amino acids, in particular L-threonine.

Summary of the Invention

The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which 15 in particular already produce L-amino acids and in which the nucleotide sequence which codes for the aspA gene is attenuated.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine; L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine. L-Threonine is particularly preferred.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or a gene or allele which codes for a

corresponding enzyme (protein) or gene, and optionally combining these measures.

By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 5 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.

The process comprises carrying out the following steps:

- 10 a) fermentation of microorganisms of the Enterobacteriaceae family in which the *aspA* gene is attenuated,
- 15 b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the Enterobacteriaceae family, and
- 15 c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.
- 20 The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are representatives of the Enterobacteriaceae family chosen
- 25 from the genera *Escherichia*, *Erwinia*, *Providencia* and *Serratia*. The genera *Escherichia* and *Serratia* are preferred. Of the genus *Escherichia* the species *Escherichia coli* and of the genus *Serratia* the species *Serratia marcescens* are to be mentioned in particular.
- 30 Suitable strains, which produce L-threonine in particular, of the genus *Escherichia*, in particular of the species *Escherichia coli*, are, for example

- Escherichia coli TF427
Escherichia coli H4578
Escherichia coli KY10935
Escherichia coli VNIIgenetika MG442
5 Escherichia coli VNIIgenetika M1
Escherichia coli VNIIgenetika 472T23
Escherichia coli BKIIM B-3996
Escherichia coli kat 13
Escherichia coli KCCM-10132
- 10 Suitable L-threonine-producing strains of the genus *Serratia*, in particular of the species *Serratia marcescens*, are, for example
- 15 *Serratia marcescens* HNr21
Serratia marcescens TLr156
15 *Serratia marcescens* T2000
- Strains from the Enterobacteriaceae family which produce L-threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to α -amino- β -hydroxyvaleric acid, resistance to 20 thialysine, resistance to ethionine, resistance to α -methylserine, resistance to diaminosuccinic acid, resistance to α -aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate, 25 resistance to purine analogues, such as, for example, 6-dimethylaminopurine, a need for L-methionine, optionally a partial and compensable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, 30 resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid, resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, 35 sensitivity to fluoropyruvate, defective threonine

- dehydrogenase, optionally an ability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feed back resistant form, enhancement 5 of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form, 10 enhancement of phosphoenol pyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.
- 15 It has been found that microorganisms of the Enterobacteriaceae family produce L-amino acids, in particular L-threonine, in an improved manner after attenuation, in particular elimination, of the aspA gene.
- The nucleotide sequences of the genes of Escherichia coli 20 belong to the prior art and can also be found in the genome sequence of Escherichia coli published by Blattner et al. (Science 277: 1453 - 1462 (1997)).
- The aspA gene is described, inter alia, by the following data:
- 25 Description: Aspartate ammonium lyase (aspartase)
EC No.: 4.3.1.1
Reference: Takagi et al.; Nucleic Acids Research 13(6): 2063-2074 (1985); Woods et al.; Biochemical Journal 237(2): 547-557 (1986);
30 Falzone et al.; Biochemistry 27(26): 9089-9093 (1988); Jayasekera et al.; Biochemistry 36(30): 9145-9150 (1997)
- Accession No.: AB000481

The nucleic acid sequences can be found in the databanks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA), the nucleotide sequence databank of the European Molecular 5 Biologies Laboratories (EMBL, Heidelberg, Germany or Cambridge, UK) or the DNA databank of Japan (DDBJ, Mishima, Japan).

The genes described in the text references mentioned can be used according to the invention. Alleles of the genes which 10 result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

To achieve an attenuation, for example, expression of the gene or the catalytic properties of the enzyme proteins can 15 be reduced or eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA 20 technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information in this respect, *inter alia*, for example, in Jensen and Hammer 25 (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15: 58-64 (1999)), Franch and Gerdes (Current Opinion in Microbiology 3: 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of 30 Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that of Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art. Examples which may be mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95: 5511-5515 (1998)), Wente and Schachmann (Journal of Biological Chemistry 266: 20833-20839 (1991)). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as 10 e.g. that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the amino acid exchange on the enzyme activity, "missense 15 mutations" or "nonsense mutations" are referred to. Insertions or deletions of at least one base pair in a gene lead to "frame shift mutations", which lead to incorrect amino acids being incorporated or translation being interrupted prematurely. If a stop codon is formed in the 20 coding region as a consequence of the mutation, this also leads to a premature termination of the translation. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known 25 textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 30 1990) or that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Suitable mutations in the genes, such as, for example, deletion mutations, can be incorporated into suitable strains by gene or allele replacement.

A conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)), of gene replacement with the aid of a conditionally replicating pSC101 derivative pMAK705. Other methods 5 described in the prior art, such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 181: 1999, 7143-7148 (1999)) or those of Boyd et al. (Journal of Bacteriology 182: 842-847 (2000)), can likewise be used.

It is also possible to transfer mutations in the particular 10 genes or mutations which affect expression of the particular genes into various strains by conjugation or transduction.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, with strains of the 15 Enterobacteriaceae family, in addition to attenuation of the aspA gene, for one or more enzymes of the known threonine biosynthesis pathway or enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate or enzymes of 20 glycolysis or PTS enzymes or enzymes of sulfur metabolism to be enhanced.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by 25 the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.

30 By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 250% or 300%, as to a maximum of 1000%. On 500%, the activity of the wild-type may still be

activity or concentration of the protein in the starting microorganism.

Thus, for example, at the same time one or more of the genes chosen from the group consisting of

- 5 • the *thrABC* operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the *pyc* gene of *Corynebacterium glutamicum* which codes for pyruvate carboxylase (WO 99/18228),
- 10 • the *pps* gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231(2): 332-336 (1992)),
- the *ppc* gene which codes for phosphoenol pyruvate carboxylase (Gene 31: 279-283 (1984)),
- 15 • the *pntA* and *pntB* genes which code for transhydrogenase (European Journal of Biochemistry 158: 647-653 (1986)),
- the *rhtB* gene which imparts homoserine resistance (EP-A-0 994 190),
- the *mgo* gene which codes for malate:quinone
- 20 • oxidoreductase (WO 02/06459),
- the *rhtC* gene which imparts threonine resistance (EP-A-1 013 765),
- the *thrE* gene of *Corynebacterium glutamicum* which codes for the threonine export protein (WO 01/92545),
- 25 • the *gdhA* gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983)),

- the *hns* gene which codes for the DNA-binding protein HLP-II (Molecular and General Genetics 212: 199-202 (1988)),
- the *pgm* gene which codes for phosphoglucomutase (Journal of Bacteriology 176: 5847-5851 (1994)),
- the *fba* gene which codes for fructose biphosphate aldolase (Biochemical Journal 257: 529-534 (1989)),
- the *ptsH* gene of the *ptsHIcrr* operon which codes for the phosphohistidine protein hexose phosphotransferase of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the *ptsI* gene of the *ptsHIcrr* operon which codes for enzyme I of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the *crr* gene of the *ptsHIcrr* operon which codes for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the *ptsG* gene which codes for the glucose-specific IIBC component (Journal of Biological Chemistry 261: 16398-16403 (1986)),
- the *lrp* gene which codes for the regulator of the leucine regulon (Journal of Biological Chemistry 266: 10768-10774 (1991)),
- the *mopB* gene which codes for 10 Kd chaperone (Journal of Biological Chemistry 261: 12414-12419 (1986)) and is also known by the name *groES*,
- the *ahpC* gene of the *ahpCF* operon which codes for the small sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),

- the ahpF gene of the ahpCF operon which codes for the large sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences USA 92: 7617-7621 (1995)),
- 5 • the cysK gene which codes for cysteine synthase A (Journal of Bacteriology 170: 3150-3157 (1988)),
- the cysB gene which codes for the regulator of the cys regulon (Journal of Biological Chemistry 262: 5999-6005 (1987)),
- 10 • the cysJ gene of the cysJIH operon which codes for the flavoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
- the cysI gene of the cysJIH operon which codes for the haemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)) and
- 15 • the cysH gene of the cysJIH operon which codes for adenylyl sulfate reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989))

can be enhanced, in particular over-expressed.

The use of endogenous genes is in general preferred. "Endogenous genes" or "endogenous nucleotide sequences" are understood as meaning the genes or nucleotide sequences present in the population of a species.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to attenuation of the aspA gene, for one or more of the genes 30 chosen from the group consisting of

- the *tdh* gene which codes for threonine dehydrogenase (Journal of Bacteriology 169: 4716-4721 (1987)),
- the *mdh* gene which codes for malate dehydrogenase (E.C. 1.1.1.37) (Archives in Microbiology 149: 36-42 (1987)),
- 5 • the gene product of the open reading frame (orf) *yjfA* (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the gene product of the open reading frame (orf) *ytfP* (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- 10 • the *pckA* gene which codes for the enzyme phosphoenol pyruvate carboxykinase (Journal of Bacteriology 172: 7151-7156 (1990)),
- the *poxB* gene which codes for pyruvate oxidase (Nucleic Acids Research 14(13): 5449-5460 (1986)),
- 15 • the *aceA* gene which codes for the enzyme isocitrate lyase (Journal of Bacteriology 170: 4528-4536 (1988)),
- the *dgsA* gene which codes for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and Biochemistry 59: 256-261 (1995)) and is also known under the name of the *mlc* gene,
- 20 • the *fruR* gene which codes for the fructose repressor (Molecular and General Genetics 226: 332-336 (1991)) and is also known under the name of the *cra* gene,
- the *rpoS* gene which codes for the sigma³⁸ factor (WO 01/05939) and is also known under the name of the *katF* gene,
- 25 • the *aceB* gene which codes for malate synthase A (Nucleic Acids Research 19(13): 9041-9050),

- the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase (Journal of Bacteriology 170(1): 89-97 (1988)) and
- the ugpB gene which codes for the periplasmic binding 5 protein of the sn-glycerol 3-phosphate transport system (Molecular Microbiology 2(6): 767-775 (1988))

to be attenuated, in particular eliminated or for the expression thereof to be reduced.

It may furthermore be advantageous for the production of L- 10 amino acids, in particular L-threonine, in addition to attenuation of the aspA gene, to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sickyta, Vanek (eds.), Academic Press, London, 15 UK, 1982).

The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch process (feed process) or the repeated fed batch process (repetitive feed process). A summary of known 20 culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und 25 periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained 30 in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (American Society for Bacteriology, 1991).

- Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as 5 e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
- 10 Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be 15 used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.
- Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus.
- 20 The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.
- 25 Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
- Basic compounds, such as sodium hydroxide, potassium 30 hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable 35 substances having a selective action, e.g. antibiotics, can

be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the 5 culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

10 The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry 30: 1190-1206 (1958)), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry 51: 1167-1174 (1979)).

15 The process according to the invention is used for the fermentative preparation of L-amino acids, such as, for example, L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

20 A pure culture of the Escherichia coli K-12 strain DH5α/pMAK705 was deposited as DSM 13720 on 8th September 2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

25 The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, ligation, Klenow and alkaline phosphatase treatment are carried out by the method of 30 Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al. (Proceedings

of the National Academy of Sciences of the United States of America 86: 2172-2175 (1989)).

The incubation temperature for the preparation of strains and transformants is 37°C. Temperatures of 30°C and 44°C 5 are used in the gene replacement method of Hamilton et al.

Example 1

Construction of the deletion mutation of the *aspA* gene

Parts of the gene regions lying upstream and downstream of the *aspA* gene and parts of the 5' and 3' region of the *aspA* 10 gene are amplified from *Escherichia coli* K12 using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the *aspA* gene and sequences lying upstream and downstream in *E. coli* K12 MG1655 (SEQ ID No. 1, Accession Number 15 AE000486 and AE000487), the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

aspA5'-1: 5' - GCTGCATCAGCACGAAATTC - 3' (SEQ ID No. 3)

aspA5'-2: 5' - CCATTACCATAACCGCGAAC - 3' (SEQ ID No. 4)

aspA3'-1: 5' - TGGCAGCAGAAGCAGGTCAG - 3' (SEQ ID No. 5)

20 *aspA3'*-2: 5' - TAGTCCAGACCGCCAGCAAC - 3' (SEQ ID No. 6)

The chromosomal *E. coli* K12 MG1655 DNA employed for the PCR is isolated according to the manufacturer's instructions with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 650 bp in size from the 5' region of 25 the *aspA* gene region (called *aspA5'*) and a DNA fragment approx. 700 bp in size from the 3' region of the *aspA* gene region (called *aspA3'*) can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with *Taq*-DNA polymerase (Qiagen-Germany, Eggenstein, Germany). The PCR products are each digested

with the vector pCR2.1-TOPO (TOPO TA Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturer's instructions and transformed into the *E. coli* strain TOP10F'. Selection of plasmid-carrying cells 5 takes place on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA, the vector pCR2.1-TOPOaspA3' is cleaved with the restriction enzymes XbaI and EcoRI. The aspA3' fragment is isolated after separation in 0.8% agarose gel with the aid of the QIAquick 10 Gel Extraction Kit (QIAGEN, Hilden, Germany). After isolation of the plasmid DNA the vector pCR2.1-TOPOaspA5' is cleaved with the enzymes EcoRV and XbaI and ligated with the aspA3' fragment isolated. The *E. coli* strain DH5 α is transformed with the ligation batch and plasmid-carrying 15 cells are selected on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA those plasmid in which the mutagenic DNA sequence shown in SEQ ID No. 7 is cloned are detected by control cleavage with the enzymes EcoRI, XbaI and HindIII. One of the plasmids is called 20 pCR2.1-TOPO Δ aspA (=pCR2.1-TOPOdeltaaspA).

Example 2

Construction of the replacement vector pMAK705 Δ aspA

The Δ aspA allele described in example 1 is isolated from the vector pCR2.1-TOPO Δ aspA after restriction with the 25 enzymes HindIII and XbaI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al., Journal of Bacteriology 171: 4617-4622 (1989)), which has been digested with the enzymes HindIII and XbaI. The ligation batch is transformed in DH5 α and plasmid-carrying 30 cells are selected on LB agar, to which 20 µg/ml chloramphenicol are added. Successful cloning is demonstrated after isolation of the plasmid DNA and cleavage with the enzymes HindIII and XbaI. The replacement 35 vector is shown in Figure 1.

Example 3

Position-specific mutagenesis of the *aspA* gene in the *E. coli* strain MG442

The L-threonine-producing *E. coli* strain MG442 is described 5 in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

For replacement of the chromosomal *aspA* gene with the plasmid-coded deletion construct, MG442 is transformed with 10 the plasmid pMAK705Δ*aspA*. The gene replacement is carried out using the selection method described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic 15 Press) with the following oligonucleotide primers:

aspA5'-1: 5' - GCTGCATCAGCACGAAATTC - 3' (SEQ ID No. 3)

aspA3'-2: 5' - TAGTCCAGACCGCCAGCAAC - 3' (SEQ ID No. 6)

After replacement has taken place, MG442 contains the form 20 of the Δ*aspA* allele shown in SEQ ID No. 8. The strain obtained is called MG442Δ*aspA*.

Example 4

Preparation of L-threonine with the strain MG442Δ*aspA*

MG442Δ*aspA* is multiplied on minimal medium with the following composition: 3.5 g/l Na₂HPO₄·2H₂O, 1.5 g/l KH₂PO₄, 25 1 g/l NH₄Cl, 0.1 g/l MgSO₄·7H₂O, 2 g/l glucose, 20 g/l agar. The formation of L-threonine is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 30 2 g/l yeast extract, 10 g/l (NH₄)₂SO₄, 1 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, 15 g/l CaCO₃, 20 g/l glucose are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on

- an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of this preculture are transinoculated into 10 ml of production medium (25 g/l $(\text{NH}_4)_2\text{SO}_4$, 2 g/l KH_2PO_4 , 1 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.03 g/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.018 g/l $\text{MnSO}_4 \cdot 1\text{H}_2\text{O}$, 30 g/l 5 CaCO_3 , 20 g/l glucose) and the batch is incubated for 48 hours at 37°C. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.
- 10 The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with ninhydrin detection.

15 The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442 Δ aspA	5.5	1.9

Brief Description of the Figure:

- Figure 1: pMAK705 Δ aspA (= pMAK705deltaaspA)
- 20 The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:
- cat: Chloramphenicol resistance gene
 - pSC101: Cloning vector, containing the lacZ gene and the plasmid pSC101
- 25

- *aspA5'*: Part of the 5' region of the *aspA* gene and the region lying upstream
- *aspA3'*: Part of the 3' region of the *aspA* gene and the region lying downstream

5 The abbreviations for the restriction enzymes have the following meaning

- EcoRI: Restriction endonuclease from *Escherichia coli*
 - HindIII: Restriction endonuclease from *Haemophilus influenza*
- 10 • XbaI: Restriction endonuclease from *Xanthomonas badrii*

What is claimed is:

1. A process for the preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:
 - 5 a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the *aspA* gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated,
 - 10 b) concentration of the desired L-amino acid in the medium or in the cells of the microorganisms, and
 - 15 c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.
2. A process as claimed in claim 1, wherein microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 20 3. A process as claimed in claim 1, wherein microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
4. A process as claimed in claim 1, wherein the expression 25 of the polynucleotide which codes for the *aspA* gene is attenuated, in particular eliminated.
5. A process as claimed in claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide *aspA* codes are 30 reduced.

6. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:
 - 6.1 the *thrABC* operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
 - 6.2 the *pyc* gene which codes for pyruvate carboxylase,
 - 6.3 the *pps* gene which codes for phosphoenol pyruvate synthase,
 - 6.4 the *ppc* gene which codes for phosphoenol pyruvate carboxylase,
 - 6.5 the *pntA* and *pntB* genes which code for transhydrogenase,
 - 6.6 the *rhtB* gene which imparts homoserine resistance,
 - 6.7 the *mqo* gene which codes for malate:quinone oxidoreductase,
 - 6.8 the *rhtC* gene which imparts threonine resistance,
 - 6.9 the *thrE* gene which codes for the threonine export protein,
 - 6.10 the *gdhA* gene which codes for glutamate dehydrogenase,
 - 6.11 the *hns* gene which codes for the DNA-binding protein HLP-II,

- 6.12 the *pgm* gene which codes for phosphoglucomutase,
- 6.13 the *fba* gene which codes for fructose biphosphate aldolase,
- 5 6.14 the *ptsH* gene which codes for the phosphohistidine protein hexose phosphotransferase,
- 6.15 the *ptsI* gene which codes for enzyme I of the phosphotransferase system,
- 10 6.16 the *crr* gene which codes for the glucose-specific IIA component,
- 6.17 the *ptsG* gene which codes for the glucose-specific IIBC component,
- 15 6.18 the *lrp* gene which codes for the regulator of the leucine regulon,
- 6.19 the *mopB* gene which codes for 10 Kd chaperone,
- 6.20 the *ahpC* gene which codes for the small sub-unit of alkyl hydroperoxide reductase,
- 20 6.21 the *ahpF* gene which codes for the large sub-unit of alkyl hydroperoxide reductase,
- 6.22 the *cysK* gene which codes for cysteine synthase A,
- 6.23 the *cysB* gene which codes for the regulator of the *cys* regulon,
- 25 6.24 the *cysJ* gene which codes for the flavoprotein of NADPH sulfite reductase,
- 6.25 the *cysI* gene which codes for the haemoprotein of NADPH sulfite reductase and

6.26 the cysH gene which codes for adenylyl sulfate reductase,

is or are enhanced, in particular over-expressed, are fermented.

5 7. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:

10 7.1 the tdh gene which codes for threonine dehydrogenase,

7.2 the mdh gene which codes for malate dehydrogenase,

15 7.3 the gene product of the open reading frame (orf) yjfA,

7.4 the gene product of the open reading frame (orf) ytfP,

7.5 the pckA gene which codes for phosphoenol pyruvate carboxykinase

20 7.6 the poxB gene which codes for pyruvate oxidase

7.7 the aceA gene which codes for isocitrate lyase,

7.8 the dgsA gene which codes for the DgsA regulator of the phosphotransferase system,

25 7.9 the fruR gene which codes for the fructose repressor,

7.10 the rpoS gene which codes for the sigma³⁸ factor,


7.11 the aceB gene which codes for malate synthase A

- 7.12 the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase and
- 7.13 the ugpB gene which codes for the periplasmic binding protein of the sn-glycerol 3-phosphate transport system

5

is or are attenuated, in particular eliminated or reduced in expression, are fermented.

Figure 1:



SEQUENCE PROTOCOL

5 <110> Degussa AG
 <120> Process for the preparation of L-amino acids using
 strains of the Enterobacteriaceae family which contain an
 attenuated *aspA* gene
 10 <130> 020269 BT
 <160> 8
 15 <170> PatentIn version 3.1
 <210> 1
 <211> 2280
 <212> DNA
 <213> *Escherichia coli*
 20 <220>
 <221> CDS
 <222> (470)..(1951)
 <223> *aspA* gene
 25 <400> 1
 gctgcatcatc cacgaaattc ttaaagccct gttacgtac cagtacata ccgataactg 60
 acgtgaatat aaccagcactg aggtcagca ataccccaa tacatggca acctgaataa 120
 30 agattgaaat ctcaatatacg acataaagga aatggcaat aaaaggttaac cagcgcaaaag 180
 gtttctcctg taatagcagc cggttaaccc cggttacctg aatgggtgc gaatcgcggt 240
 35 tagcttatat tgggtcatt agcaaaattt caagatgtt ggcactat tttggtagt 300
 aatcccaaag cggtgatcta tttcacaaat taataattaa gggtaaaaaa ccgacactta 360
 40 aagtgatcca gattacggta gaaatcctca agcagcatat gatctcggtt atccggtcga 420
 tgcagggat aatcgtcggt cgaaaaacat tcgaaaccac atatattct gtg tgg tta 478
 Met Cys Leu
 1
 45 aag caa atc att ggc agc ttg aaa aag aag gtt cac atg tca aac aac 526
 Lys Gln Ile Ile Gly Ser Leu Lys Lys Val His Met Ser Asn Asn
 5 10 15
 50 att cgt atc gaa gaa gat ctg ttg ggt acc agg gaa gtt cca gct gat 574
 Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu Val Pro Ala Asp
 20 25 30 35
 gcc tac tat ggt gtt cac act ctg aga gca att gaa aac ttc tat atc 622
 Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu Asn Phe Tyr Ile
 40 45 50
 55 agc aac aac aaa atc agt gat att cct gaa ttt gtt cgc ggt atg gta 670
 Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val Arg Gly Met Val
 55 60 65
 60 atg gtt aaa aaa gcc gca gct atg gca aac aaa gag ctg caa acc att 718

	cct aaa agt gta gcg aat gcc atc att gcc gca tgt gat gaa gtc ctg Pro Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys Asp Glu Val Leu 85 90 95	766
5	aac aac gga aaa tgc atg gat cag ttc ccg gta gac gtc tac cag ggc Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp Val Tyr Gln Gly 100 105 110 115	814
10	ggc gca ggt act tcc gta aac atg aac acc aac gaa gtg ctg gcc aat Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu Val Leu Ala Asn 120 125 130	862
15	atc ggt ctg gaa ctg atg ggt cac caa aaa ggt gaa tat cag tac ctg Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu Tyr Gln Tyr Leu 135 140 145	910
20	aac ccg aac gac cat gtt aac aaa tgt cag tcc act aac gac gcc tac Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr Asn Asp Ala Tyr 150 155 160	958
25	ccg acc ggt ttc cgt atc gca gtt tac tct tcc ctg att aag ctg gta Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu Ile Lys Leu Val 165 170 175	1006
30	gat gcg att aac caa ctg cgt gaa ggc ttt gaa cgt aaa gct gtc gaa Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg Lys Ala Val Glu 180 185 190 195	1054
35	ttc cag gac atc ctg aaa atg ggt cgt acc cag ctg cag gac gca gta Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu Gln Asp Ala Val 200 205 210	1102
40	ccg atg acc ctc ggt cag gaa ttc cgc gct ttc agc atc ctg ctg aaa Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser Ile Leu Leu Lys 215 220 225	1150
45	gaa gaa gtg aaa aac atc caa cgt acc gct gaa ctg ctg gaa gtt Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu Leu Glu Val 230 235 240	1198
50	aac ctt ggt gca aca gca atc ggt act ggt ctg aac acg ccg aaa gag Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn Thr Pro Lys Glu 245 250 255	1246
55	tac tct ccg ctg gca gtg aaa aaa ctg gct gaa gtt act ggc ttc cca Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val Thr Gly Phe Pro 260 265 270 275	1294
60	tgc gta ccg gct gaa gac ctg atc gaa gcg acc tct gac tgc ggc gct Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser Asp Cys Gly Ala 280 285 290	1342
65	tat gtt atg gtt cac ggc gcg ctg aaa cgc ctg gct gtg aag atg tcc Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala Val Lys Met Ser 295 300 305	1390
70	aaa atc tgt aac gac ctg cgc ttg ctc tct tca ggc cca cgt gcc ggc Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly Pro Arg Ala Gly 310 315 320	1438
75	ctg aac gag atc aac ctg ccg gaa ctg cag gcg ggc tct tcc atc atg Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly Ser Ser Ile Met 325 330 335	1486

	cca gct aaa gta aac ccg gtt gtt ccg gaa gtg gtt aac cag gta tgc Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val Asn Gln Val Cys 340 345 350 355	1534
5	ttc aaa gtc atc ggt aac gac acc act gtt acc atg gca gca gaa gca Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met Ala Ala Glu Ala 360 365 370	1582
10	ggt cag ctg cag ttg aac gtt atg gag ccg gtc att ggc cag gcc atg Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile Gly Gln Ala Met 375 380 385	1630
15	ttc gaa tcc gtt cac att ctg acc aac gct tgc tac aac ctg ctg gaa Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr Asn Leu Leu Glu 390 395 400	1678
20	aaa tgc att aac ggc atc act gct aac aaa gaa gtg tgc gaa ggt tac Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val Cys Glu Gly Tyr 405 410 415	1726
25	gtt tac aac tct atc ggt atc gtt act tac ctg aac ccg ttc atc ggt Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn Pro Phe Ile Gly 420 425 430 435	1774
30	cac cac aac ggt gac atc gtg ggt aaa atc tgc gaa acc ggt aag His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala Glu Thr Gly Lys 440 445 450	1822
35	agt gta cgt gaa gtc gtt ctg gaa cgc ggt ctg ttg act gaa gcg gaa Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu Thr Glu Ala Glu 455 460 465	1870
40	ctt gac gat att ttc tcc gta cag aat ctg atg cac ccg gct tac aaa Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His Pro Ala Tyr Lys 470 475 480	1918
45	gca aaaa cgc tat act gat gaa agc gaa cag taa tcgtacaggg tagtacaaat Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln 485 490	1971
50	aaaaaaaggca cgtcagatga cgtgccttt ttcttgtag cagtaactta aaaataacaa tctaatatca acttggtaaa aaacaaggaa ggctaataatg ctatggtag aactcatcat tgcattatcc attatcatgg cggattatgcg cgtatattct gccatgcagg ttgtggcgg tctggacta	2031 2091 2151 2211 2271 2280
55	<210> 2 <211> 493 <212> PRT <213> Escherichia coli	
60	<400> 2 Met Cys Leu Lys Gln Ile Ile Gly Ser Leu Lys Lys Val His Met 1 5 10 15 Ser Asn Asn Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu Val 20 25 30	

Pro Ala Asp Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu Asn
 35 40 45

5 Phe Tyr Ile Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val Arg
 50 55 60

Gly Met Val Met Val Lys Lys Ala Ala Ala Met Ala Asn Lys Glu Leu
 65 70 75 80

10 Gln Thr Ile Pro Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys Asp
 85 90 95

Glu Val Leu Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp Val
 100 105 110

15 Tyr Gln Gly Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu Val
 115 120 125

20 Leu Ala Asn Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu Tyr
 130 135 140

Gln Tyr Leu Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr Asn
 145 150 155 160

25 Asp Ala Tyr Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu Ile
 165 170 175

Lys Leu Val Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg Lys
 180 185 190

30 Ala Val Glu Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu Gln
 195 200 205

Asp Ala Val Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser Ile
 35 210 215 220

Leu Leu Lys Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu Leu
 225 230 235 240

40 Leu Glu Val Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn Thr
 245 250 255

Pro Lys Glu Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val Thr
 260 265 270

45 Gly Phe Pro Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser Asp
 275 280 285

Cys Gly Ala Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala Val
 50 290 295 300

Lys Met Ser Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly Pro
 305 310 315 320

55 Arg Ala Gly Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly Ser
 325 330 335

Ser Ile Met Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val Asn
 60 340 345 350

Gln Val Cys Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met Ala
 355 360 365

65 Ala Glu Ala Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile Gly
 370 375 380

Gln Ala Met Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr Asn
 385 390 395 400

5 Leu Leu Glu Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val Cys
 405 410 415

Glu Gly Tyr Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn Pro
 420 425 430

10 Phe Ile Gly His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala Glu
 435 440 445

Thr Gly Lys Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu Thr
 15 450 455 460

Glu Ala Glu Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His Pro
 465 470 475 480

20 Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln
 485 490

<210> 3
 <211> 20
 25 <212> DNA
 <213> artificial sequence

<220>
 <221> Primer
 30 <222> (1)..(20)
 <223> aspA5'-1

<400> 3
 gctgcatcatg cacgaaattc 20

35 <210> 4
 <211> 20
 <212> DNA
 40 <213> artificial sequence

<220>
 <221> Primer
 <222> (1)..(20)
 45 <223> aspA5'-2

<400> 4
 ccattaccat accgcgaaca 20

50 <210> 5
 <211> 20
 <212> DNA
 <213> artificial sequence

55 <220>
 <221> Primer
 <222> (1)..(20)
 <223> aspA3'-1

60 <400> 5
 tggcagcaga agcaggtcag 20

```

<210> 6
<211> 20
<212> DNA
<213> artificial sequence
5

<220>
<221> Primer
<222> (1)..(20)
10 <223> aspA3'-2

<400> 6
tagtccagac cgccagcaac 20

15 <210> 7
<211> 1563
<212> DNA
<213> Escherichia coli

20 <220>
<221> misc_feature
<222> (1)..(1563)
<223> mutagenic DNA

25 <220>
<221> misc_feature
<222> (1)..(60)
<223> technical DNA / residues of polylinker sequence

30 <220>
<221> misc_feature
<222> (61)..(734)
<223> parts of the 5' region of the aspA gene and regions lying upstream

35 <220>
<221> misc_feature
<222> (735)..(799)
<223> technical DNA / residues of polylinker sequence

40 <220>
<221> misc_feature
<222> (800)..(1511)
<223> parts of the 3' region of the aspA gene and regions lying downstream

45 <220>
<221> misc_feature
<222> (1512)..(1563)
<223> technical DNA / residues of polylinker sequence

50 <400> 7
agcttggtag ctagtccgaa tccactatgtt acggccgcca gtgtgcttggaa attcgccctt 60
gctgcatcag cacgaaattc tttaaaggccct ggtaatgtac cagtgacata ccgataactg 120
55 acgtgaatat aaccagcactg agggtcagca ataccccaa tacatggca acctgaataa 180
agattgaaat ctcaatatacg acataaaagggaa aatggcaat aaaaggtaac cagcgcaaaag 240
60 gtttctccgt taatagcagc cggtaaccc cggctacctg aatgggttgc gaatcgcggt 300
tagcttatat tgtggtcatt agcaaaaattt caagatgttt ggcgtactat ttttggtagt 360
aatcccaaag cggtgatcta tttcacaaat taataattaa gggtaaaaaa ccgacactta 420
65 aagtgtatcca gattacggta gaaatcctca agcagcatat gatctcggtt attcggtcga 480

```

5	tgccggggat aatcgctcggt cgaaaaacat tcgaaaccac atatattctg tgggtttaaa gcaaatcatt ggcagcttga aaaagaaggt tcacatgtca aacaacatcc gtatcgaaaa agatctgttg ggtaccaggg aagttccagc tgatgcctac tatgggtttc acactctgag agcgattgaa aacttctata tcagcaacaa caaaatcagt gatattcctg aatttggcg	540 600 660 720
10	cggtatggta atggaagggc gaattctgca gatctcgat ccactagtaa cggccgcccag tgtgctggaa ttgcgcctt ggcagcagaa gcaggtcagc tgcaaggtaa cgttatggag ccggtcattt gccaggccat gttcaatcc gttcacatcc tgaccaacgc ttgcataaac	780 840 900
15	ctgctggaaa aatgcattaa cggcatcaact gctaacaaag aagtgtgcga aggttacgaa tacaactcta tcggtatcgt tacttacctg aaccctgtca tcggtcacca caacggtgac	960 1020
20	atcggtggta aaatctgtgc cggaaaccgg aagagtgtac gtgaagtcgt tctggAACGC ggtctgttga ctgaagcgga acttgacgtat ttttctccg tacagaatct gatgcacccg	1080 1140
25	gcttacaaag caaaacgcta tactgatgaa agcgaacagt aatcgtagac ggttagtacaa ataaaaaagg cacgtcagat gacgtgcctt ttttcttgcg agcagtaact taaaaataac	1200 1260
30	aatctaataat caacttggta aaaaacaagg aaggctaata tgctagttgt agaactcatc atagtttgc tggcgatctt cttggcgcc agattggggg gaataggat tggttttgca	1320 1380
35	ggcggattgg gggtgctgg tcttgcgtt attggcgtaa aaccctgtaa catcccggt gatgtcatct ccattatcat ggcgttatac gccgctattt ctgcccattgc ggttgctggc ggtctggact aaaggccgaa ttctgcagat atccatcaca ctggcgccg ctcgagcatg	1440 1500 1560
	cat	1563
40	<210> 8 <211> 653 <212> DNA <213> Escherichia coli	
45	<220> <221> misc_feature <222> (1)..(653) <223> mutagenic DNA	
50	<220> <221> misc_feature <222> (1)..(3) <223> start codon of the deltaaspA allele	
55	<220> <221> misc_feature <222> (1)..(205) <223> 5' region of the deltaaspA allele	
60	<220> <221> misc_feature <222> (206)..(270) <223> technical DNA / residues of the polylinker sequence	

5 <220>
<221> misc_feature
<222> (271)..(653)
<223> 3' region of the deltaaspA allele

10 <220>
<221> misc_feature
<222> (651)..(653)
<223> stop codon of the deltaaspA allele

15 <400> 8
gtgtgttaa agcaaatcat tggcagcttg aaaaagaagg ttcacatgtc aaacaacatt 60
cgtatcgaag aagatctgtt gggtaaccagg gaagttccag ctgatgccta ctatggtgtt 120
cacactctga gagcgattga aaacttctat atcagcaaca acaaaatcag tgatattcct 180
gaatttgttc gcgttatggt aatggaaaggc cgaattctgc agatctcggc tccactagta 240
20 acggccgcca gtgtgctggc attcgccctt tggcagcaga agcaggtcag ctgcagttga 300
acgttatggc gcccgtcatt ggcaggcaca tgttcgaatc cgttcacatt ctgaccaacgc 360
25 cttgctacaa ccttgtggaa aaatgcatta acggcatcac tgctaacaaa gaagtgtgcg 420
aaggttacgt ttacaactct atcggtatcg ttacttacct gaaccgttc atcggtcacc 480
acaacggtga catcggtgggt aaaatctgtg ccgaaaccgg taagagtgtc cgtgaagtcg 540
30 ttcttggAACG CGGTCTGTG ACTGAAGCGG AACTTGACGA TATTTCTCC GTACAGAACATC 600
tgatgcaccc ggcttacaaa gcaaaacgcatactgtga aagcgaacag taa 653

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008603 A3

(51) International Patent Classification⁷: C13
13/12, 13/14, 13/06, 13/10, 13/20, 13/22, 13/24

(21) International Application Number: PCT/EP02/07351

(25) [EU](#) | [Legal](#) | [Help](#) | [English](#)

(26) Publication Language: English

(30) Priority Data:

(36) Priority Data:
101 35 051.1 18 July 2001 (18.07.2001) DE
60/306.867 23 July 2001 (23.07.2001) US

(71) **Applicant (for all designated States except US): DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): HERMANN, Thomas
[DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).

(74) **Common Representative:** DEGUSSA AG; Intellectual Property Management, Patents and Trademarks, Location Hanau, P.O.Box 13 45, 63403 Hanau (VN).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*


Published:

— with international search report

- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEA FAMILY WHICH CONTAIN AN ATTENUATED ASPA GENE



WO 03/008603 A3

(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the *aspA* gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated, b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.



(88) Date of publication of the international search report:

31 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C12P13/08	C12P13/12	C12P13/14	C12P13/06	C12P13/10
	C12P13/20	C12P13/22	C12P13/24		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WOODS S A ET AL: "DIFFERENTIAL ROLE OF THE <i>ESCHERICHIA COLI</i> FUMARASES AND FNR-DEPENDENT EXPRESSION OF FUMARASE B AND ASPARTASE" FEMS (FEDERATION OF EUROPEAN MICROBIOLOGICAL SOCIETIES) MICROBIOLOGY, vol. 48, no. 1-2, 1987, pages 219-224, XP008018171 1987 ISSN: 0378-1097 the whole document</p> <p>—/—</p>	1-7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

11 June 2003

24/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Kools, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MENKEL E ET AL: "INFLUENCE OF INCREASED ASPARTATE AVAILABILITY ON LYSINE FORMATION BY A RECOMBINANT STRAIN OF CORYNEBACTERIUM-GLUTAMICUM AND UTILIZATION OF FUMARATE" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 55, no. 3, 1989, pages 684-688, XP008017685 ISSN: 0099-2240 abstract	1-7
A	US 4 347 318 A (MIWA KIYOSHI ET AL) 31 August 1982 (1982-08-31) the whole document	1-7
A	CHAO YUN-PENG ET AL: "Selective production of L-aspartic acid and L-phenylalanine by coupling reactions of aspartase and aminotransferase in Escherichia coli." ENZYME AND MICROBIAL TECHNOLOGY, vol. 27, no. 1-2, July 2000 (2000-07), pages 19-25, XP002243820 ISSN: 0141-0229 the whole document	1-7
A	VIPOND RICHARD ET AL: "Defined deletion mutants demonstrate that the major secreted toxins are not essential for the virulence of Aeromonas salmonicida." INFECTION AND IMMUNITY, vol. 66, no. 5, May 1998 (1998-05), pages 1990-1998, XP002243821 ISSN: 0019-9567 abstract	1-7
A	LANDGRAF J R ET AL: "THE ROLE OF H-NS IN ONE CARBON METABOLISM" BIOCHIMIE, MASSON, PARIS, FR, vol. 76, no. 10/11, 1994, pages 1063-1070, XP008014239 ISSN: 0300-9084 page 1064, column 1, last paragraph	1-7
E	WO 03 008616 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008604 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008602 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07351

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03 008600 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/07351

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4347318	A	31-08-1982	JP	1029559 B	12-06-1989
			JP	1552063 C	23-03-1990
			JP	55131397 A	13-10-1980
			DE	3012921 A1	23-10-1980
			FR	2453216 A1	31-10-1980
			GB	2049670 A ,B	31-12-1980
WO 03008616	A	30-01-2003	DE	10135051 A1	06-02-2003
			WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
			WO	03008604 A2	30-01-2003
			WO	03008616 A2	30-01-2003
WO 03008604	A	30-01-2003	DE	10135051 A1	06-02-2003
			WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
			WO	03008604 A2	30-01-2003
			WO	03008616 A2	30-01-2003
WO 03008602	A	30-01-2003	DE	10135051 A1	06-02-2003
			WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
			WO	03008604 A2	30-01-2003
			WO	03008616 A2	30-01-2003
WO 03008600	A	30-01-2003	DE	10135051 A1	06-02-2003
			WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
			WO	03008604 A2	30-01-2003
			WO	03008616 A2	30-01-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.